SPOTLIGHT -
First biologic approved for the treatment of allergic asthma
FDA Approves Drop for Drug-Induced Dilation of the Pupils
Ryzumi is expected to be available in the first half of 2024. Pricing will be available around the time of launch.
FDA Assigns Review Date for Dupixent in Young Children with Eosinophilic Esophagitis
The FDA has assigned a target action date of Jan. 31, 2024, for Dupixent to treat children 1 to 11 years of age with the inflammatory condition eosinophilic esophagitis.
FDA Issues Complete Response for Udenyca OnBody
The FDA is conducting an ongoing inspection of a third-party filler.
FDA Approves Jardiance for Patients with Chronic Kidney Disease
Jardiance is currently available to treat patients with type 2 diabetes, end stage renal disease and heart failure. It has a list price of $570.48 for a month supply.
Drugs to Watch: Cancer
Developing novel drugs to treat cancer remains a strong focus for drug developers. Several first-in-class therapies have become available over the last few months.
FDA Issues Complete Response for Epinephrine Nasal Spray
The FDA has requested an additional study. ARS Pharmaceuticals plans to appeal the decision.
